Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Blood (2021) 138 (22): 2290–2293.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals